Global Acyclovir

Nchi: Nyuzilandi

Lugha: Kiingereza

Chanzo: Medsafe (Medicines Safety Authority)

Viambatanisho vya kazi:

Aciclovir 400mg

Inapatikana kutoka:

Global Pharmaceuticals Limited

INN (Jina la Kimataifa):

Aciclovir 400 mg

Kipimo:

400 mg

Dawa fomu:

Tablet

Tungo:

Active: Aciclovir 400mg Excipient: Colloidal silicon dioxide Magnesium stearate Microcrystalline cellulose Povidone Sodium starch glycolate

Vitengo katika mfuko:

Blister pack, PVC, (4x14), 56 tablets

Darasa:

Prescription

Dawa ya aina:

Prescription

Viwandani na:

Lek Pharmaceuticals d.d.

Bidhaa muhtasari:

Package - Contents - Shelf Life: Blister pack, PVC, (4x14) - 56 tablets - 48 months from date of manufacture stored at or below 25°C - Bottle, plastic, 50 tablet, HDPE, pp cap - 50 tablets - 48 months from date of manufacture stored at or below 25°C - Bottle, plastic, 56 tablet, HDPE, pp cap - 56 tablets - 48 months from date of manufacture stored at or below 25°C - Bottle, plastic, 100 tablet, HDPE, pp cap - 100 tablets - 48 months from date of manufacture stored at or below 25°C - Bottle, plastic, 250 tablet, HDPE, pp cap - 250 tablets - 48 months from date of manufacture stored at or below 25°C - Bottle, plastic, 500 tablet, HDPE, pp cap - 500 tablets - 48 months from date of manufacture stored at or below 25°C

Idhini ya tarehe:

1998-08-24

Tabia za bidhaa

Medsafe Logo
INFORMATION FOR
HEALTH PROFESSIONALS
Home  |  Consumers  |  Health Professionals  |  Regulatory  |  Other  |  Hot Topics  |  Search
Data Sheet
GLOBAL ACYCLOVIR
Acyclovir 400mg and 800mg tablets
Presentation
GLOBAL ACYCLOVIR 400mg tablets are white, oval biconvex tablets identified ACY400 on one
side. Each tablet contains 400mg acyclovir and typically weighs 525mg.
GLOBAL ACYCLOVIR 800mg tablets are white, oval biconvex tablets identified ACY800 on one
side and a breakline on the other. Each tablet contains 800mg acyclovir and typically weighs 1050mg.
Uses
Actions
Acyclovir is a synthetic purine nucleoside analogue with in vitro and in vivo inhibitory activity against
human herpes viruses, varicella-zoster virus, Epstein-Barr virus and to a lesser extent cytomegalovirus.
Acyclovir has an antiviral effect on herpes simplex viruses and varicella zoster virus resulting from its
interference with DNA synthesis leading to inhibition of virus replication. The exact mechanism of
acyclovir action in other susceptible viruses has not been fully elucidated.
Acyclovir triphosphate is the pharmacologically active metabolite of the drug. The initial
phosphorylation of acyclovir to acyclovir monophosphate is catalysed by virus-induced thymidine
kinase. Thus selective activation of the drug is achieved principally in infected cells. Further
phosphorylation to acyclovir diphosphate is catalysed via cellular guanylate kinase and then
phosphorylation to acyclovir triphosphate is catalysed via other intracellular enzymes (phosphoglycerate
kinase, pyruvate kinase, phosphoenolpyruvate carboxykinase). The extent of formation of acyclovir
monophosphate, diphosphate and triphosphate is directly related to the concentration of acyclovir in the
cellular culture medium. In vitro studies indicate tha